Abstract
OBJECTIVE: Adrenal masses usually represent benign and nonfunctional adrenal adenomas; however, primary or metastatic malignancy should also be considered. Discovery of an adrenal mass needs further evaluation in order to exclude malignancy and hormonal secretion. We present a rare case of a possibly primary adrenal malignant melanoma with imaging and biochemical features of a pheochromocytoma. CASE REPORT: A 61-year-old male farmer was referred for evaluation of a mass in the right supraclavicular region and a left adrenal lesion. The patient had a history of a multifocal papillary and medullary thyroid carcinoma. Laboratory tests revealed increased 24hour urinary dopamine and also increased serum calcitonin and neuron specific enolase. A pathology report of the resected right supraclavicular mass and left adrenal showed a malignant melanoma. CONCLUSION: This is a case of a possibly primary adrenal malignant melanoma with imaging and biochemical features of a pheochromocytoma. Although this case is very rare and there are rigid diagnostic criteria for the diagnosis of primary adrenal melanoma, it underlines the fact that the differential diagnosis of a dopamine secreting adrenal mass should include primary or metastatic malignant melanoma in order to determine the best diagnostic approach for the patient and select the most appropriate surgical management.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Wohllk N, Schweizer H, Erlic Z, et al, 2010 Multiple endocrine neoplasia type 2. Best Pract Res Clin Endocrinol Metab 24: 371–377.
Ng VW, Ma RC, So WY, et al, 2010 Evaluation of functional and malignant adrenal incidentalomas. Arch Intern Med 170: 2017–2020.
Zeiger MA, Siegelman SS, Hamrahian AH, 2011 Medical and Surgical Evaluation and Treatment of Adrenal Incidentalomas. J Clin Endocrinol Metab 96: 2004–2015.
Muth A, Persson F, Jansson S, et al, 2010 Prognostic factors for survival after surgery for adrenal metastasis. Eur J Surg Oncol 36: 699–704.
Bradley CT, Strong VE, 2014 Surgical management of adrenal metastasis. J Surg Oncol 109: 31–35.
Hofmann U, Szedlak M, Rittgen W, Jung EG, Schadendorf D, 2002 Primary staging and follow-up in melanoma patients — monocenter evaluation of methods, costs and patient survival. Br J Cancer 87: 151–157.
Atallah E, Flaherty L, 2005 Treatment of metastatic malignant melanoma. Curr Treat Options Oncol 6: 185–193.
Avgerinos DV, Nazarian M, Scherr DS, Girardi LN, 2012 Primary adrenal melanoma with inferior vena cava thrombus. Ann Thorac Surg 94: 2108–2110.
Ejaz S, Shawa H, Henderson SA, Habra MA, 2013 Melanoma of unknown primary origin presenting as a rapidly enlarging adrenal mass. BMJ Case Rep 19: 2013. pii: bcr2013009727.
Gonzalez-Saez L, Pita-Fernandez S, Lorenzo-Patino M, Arnal-Monreal F, Machuca-Santacruz J, Romero-Gonzalez J, 2011 Primary melanoma of the adrenal gland: a case report and review of the literature. J Med Case Rep 5: 273.
Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW, 2008 Immunohistochemical characteristics of melanoma. J Cutan Pathol 35: 433–444.
Granero LE, Al-Lawati T, Bobin J-Y, 2004 Primary Melanoma of the Adrenal Gland, a Continuous Dilemma: Report of a Case. Surg Today 34: 554–556.
Castillo OA, Vitagliano G, Kerkebe M, Parma P, Pinto I, Diaz M, 2007 Laparoscopic Adrenalectomy for Suspected Metastasis of Adrenal Glands: Our Experience. Urology 69: 637–641.
Poirier É, Thauvette D, Hogue JC, 2013 Management of Exclusively Dopamine-Secreting Abdominal Pheochromocytomas. J Am Coll Surg 216: 340–346.
Dubois LA, Gray DK, 2005 Dopamine-secreting pheochromocytomas: in search of a syndrome. World J Surg 29: 909–913.
Eisenhofer G, Goldstein DS, Sullivan P, et al, 2005 Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxy-tyramine. J Clin Endocrinol Metab 90: 2068–2075.
Collinson FJ, Lam TK, Bruijn WMJ, et al, 2008 Long-term Survival and Occasional Regression of Distant Melanoma Metastases after Adrenal Metastasectomy. Ann Surg Oncol 15: 1741–1749.
Lo CY, Van Heerden JA, Soreide JA, et al, 1996 Adrenalectomy for metastatic disease to the adrenal glands. Br J Surg 83: 528–531.
Baudin E, Gigliotti A, Ducreux M, et al, 1998 Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer 78: 1102–1107.
Tofani A, Cioffi RP, Sciuto R, et al, 1997 S-100 and NSE as serum markers in melanoma. Acta Oncol 36: 761–764.
Sisson JC, Yanik GA, 2012 Theranostics: evolution of the radiopharmaceutical meta-iodobenzylguanidine in endocrine tumors. Semin Nucl Med 42: 171–184.
Castellani MR, Seregni E, Maccauro M, et al, 2008 MIBG for diagnosis and therapy of medullary thyroid carcinoma: is there still a role? Q J Nucl Med Mol Imaging 52: 430–440.
Tanas MR, Rubin BP, 2009 Malignant neuroectodermal tumor with melanocytic and rhabdomyoblastic differentiation. Rare Tumors 1(2) e26 doi: 10.4081/rt.2009.e26.
McEwan M, Parsons PG, 1987 Inhibition of Melanization in Human Melanoma Cells by a Serotonin Uptake Inhibitor. J Invest Dermatol 89: 82–86.
Hinterberger H, Freedman A, Barthoeomew RJ, 1972 Precursors of melanin in the blood and urine in malignant melanoma. Clin Chim Acta 9: 395–400.
Voorhess ML, 1970 Urinary excretion of DOPA and metabolites by patients with melanoma. Cancer 26: 146–149.
Mackenzie IS, Ashby MJ, Donovan T, Voutnis DD, Brown MJ, 2006 Bilateral adrenal masses: pheochromocytoma or melanoma? J R Soc Med 99: 153–155.
Leung K, Stamm M, Raja A, Low G, 2013 Pheochromocytoma: the range of appearances on ultrasound, CT, MRI, and functional imaging. AJR Am J Roentgenol 200: 370–378.
Van Berkel A, Pacak K, Lenders JW, 2014 Should every patient diagnosed with a pheochromocytoma have a 123I-MIBG scintigraphy? Clin Endocrinol (Oxf) 81: 329–333.
Zissimopoulos A, Karpouzis A, Kouskoukis C, 2009 Iotandium-111 pentetreotide scintigraphy and CT scans after 3 years in the follow-up of patients with malignant melanoma. Hell J Nucl Med 12: 142–145.
Ilias I, Sahdev A, Reznek RH, Grossman AB, Pacak K, 2007 The optimal imaging of adrenal tumours: a comparison of different methods. Endocr Relat Cancer 14: 587–599.
Proye C, Fossati P, Fontaine P, et al, 1986 Dopamine-secreting pheochromocytoma: an unrecognized entity? Classification of pheochromocytomas according to their type of secretion. Surgery 100: 1154–1162.
Ozcan Kara P, Kara T, Kara Gedik G, et al, 2011 The role of fluorodeoxyglucose positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions. Nucl Med Commun 32: 106–112.
Ziai J, Hui P, 2012 BRAF mutation testing in clinical practice. Expert Rev Mol Diagn 12: 127–138.
Carstens PHB, Kuhns JG, Ghazi C, 1984 Primary malignant melanomas of the lung and adrenal. Hum Pathol 15: 910–914.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Barmpari, M.E., Savvidis, C., Dede, A.D. et al. Adrenal malignant melanoma masquerading as a pheochromocytoma in a patient with a history of a multifocal papillary and medullary thyroid carcinoma. Hormones 15, 283–290 (2016). https://doi.org/10.14310/horm.2002.1653
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.14310/horm.2002.1653